Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingJun 7, 2023Acetic Acid Otic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0781-2023Class IIOngoingJun 7, 2023Acetaminophen & Codeine Phosphate Oral Solution 120mg/12mg/5mLCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0780-2023Class IIOngoingJun 7, 2023Atropine Sulfate Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0779-2023Class IIITerminatedJun 7, 2023Phenylephrine HCl 20 mg added to 0.9% Sodium Chloride 250mL BagProduct Mix up; Product was compounded in 250 mL 5% Dextrose instead of 250 mL 0.9% Sodium ChlorideNew England Life Care, Inc. dba Advanced Compounding Solutions · D-0778-2023Class IITerminatedJun 7, 2023Sodium Chloride 0.9% InjectionLack of assurance of sterility: The product was potentially exposed to below-recommended storage temperatures, which may cause leaks in the packaging.Fresenius Medical Care Holdings, Inc. · D-0777-2023Class IIOngoingJun 7, 2023HYDROmorphone HCl 10 mg in 0.9% Sodium ChloridgeCGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that...SSM Health Care St. Louis DBA SSM St. Clare Health Center · D-0776-2023Class IIOngoingJun 7, 2023Safe tussin PMCGMP Deviations: Use of non-food grade lubricant in mixing vessel.Denison Pharmaceuticals, LLC · D-0775-2023Class IIOngoingJun 7, 2023Pin-Away PYRENTAL PAMOATECGMP Deviations: Use of non-food grade lubricant in mixing vessel.Denison Pharmaceuticals, LLC · D-0774-2023Class IIOngoingJun 7, 2023Colic CalmCGMP Deviations: Use of non-food grade lubricant in mixing vessel.Denison Pharmaceuticals, LLC · D-0773-2023Class IIOngoingJun 7, 2023Safe tussin DMCGMP Deviations: Use of non-food grade lubricant in mixing vessel.Denison Pharmaceuticals, LLC · D-0772-2023Class IIOngoingMay 31, 2023Tirzepatide 10 mg/0.5 mL Sterile Solution-2 mL VialSub-potent DrugRevive Rx LLC dba Revive Rx Pharmacy · D-0771-2023Class IIITerminatedMay 31, 2023Fentanyl Buccal Tablets CIILabeling: Incorrect or Missing Package InsertTeva Pharmaceuticals USA Inc · D-0770-2023Class IIITerminatedMay 31, 2023Fentanyl Buccal Tablets CIILabeling: Incorrect or Missing Package InsertTeva Pharmaceuticals USA Inc · D-0769-2023Class IIITerminatedMay 31, 2023Fentanyl Buccal Tablets CIILabeling: Incorrect or Missing Package InsertTeva Pharmaceuticals USA Inc · D-0768-2023Class IIITerminatedMay 31, 2023Fentanyl Buccal Tablets CIILabeling: Incorrect or Missing Package InsertTeva Pharmaceuticals USA Inc · D-0767-2023Class IIITerminatedMay 31, 2023Fentanyl Buccal Tablets CIILabeling: Incorrect or Missing Package InsertTeva Pharmaceuticals USA Inc · D-0766-2023Class IICompletedMay 31, 2023Pain RelieverFailed Impurities/Degradation Specifications: firm's investigation due to customer complaints for discoloration found that the product was out of specification for an...Aurobindo Pharma USA Inc. · D-0765-2023Class IIOngoingMay 31, 2023Nafcillin for InjectionLack of Assurance of SterilitySagent Pharmaceuticals Inc · D-0764-2023Class IIOngoingMay 31, 2023Nafcillin for InjectionLack of Assurance of SterilitySagent Pharmaceuticals Inc · D-0763-2023Class IIOngoingMay 31, 2023Nafcillin for InjectionLack of Assurance of SterilitySagent Pharmaceuticals Inc · D-0762-2023Class IITerminatedMay 31, 2023buPROPrion Hydrochloride Extended-Release TabletsFailed Dissolution Specifications; during stability testingSun Pharmaceutical Industries Inc · D-0761-2023Class IITerminatedMay 31, 2023FOAMING HAND SANITIZERCGMP Deviations: FDA analysis found product to contain acetaldehyde and acetal above specification limits.Alpha Aromatics · D-0760-2023Class IITerminatedMay 31, 2023Glimepiride TabletsCGMP Deviations: recalling drug products following an FDA inspection.Amerisource Health Services LLC · D-0759-2023Class IITerminatedMay 31, 2023Glimepiride TabletsCGMP Deviations: recalling drug products following an FDA inspection.Amerisource Health Services LLC · D-0758-2023Class IITerminatedMay 31, 2023Glimepiride TabletsCGMP Deviations: recalling drug products following an FDA inspection.Amerisource Health Services LLC · D-0757-2023Class IIITerminatedMay 31, 2023Methylprednisolone Acetate Injectable SuspensionLabeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only)...Amneal Pharmaceuticals of New York, LLC · D-0756-2023Class IITerminatedMay 31, 2023HyperLyte CR InjectionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0755-2023Class IITerminatedMay 31, 2023HyperLyte CR InjectionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0754-2023Class IITerminatedMay 31, 2023Lidocaine 2% HCl InjLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0753-2023Class IITerminatedMay 31, 2023Potassium Acetate InjectionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0752-2023Class IITerminatedMay 31, 2023Sodium Phosphates Injection 4 mEq/3 mMol/mLLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0751-2023Class IITerminatedMay 31, 2023MSA 7.84% MSG 8.56%Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0750-2023Class IITerminatedMay 31, 2023vasopressin 50 units added to 0.9% sodium chloride 50 mL*Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0749-2023Class IITerminatedMay 31, 2023vasopressin 40 units added to 0.9% sodium chloride 100 mL*Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0748-2023Class IITerminatedMay 31, 2023vasopressin 20 units added to 0.9% sodium chloride 100 mL*Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0747-2023Class IITerminatedMay 31, 2023heparin added to 0.9% sodium chlorideLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0746-2023Class IITerminatedMay 31, 2023NORepinephrine added to 0.9% sodium chlorideLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0745-2023Class IITerminatedMay 31, 2023NORepinephrine added to 0.9% sodium chlorideLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0744-2023Class IITerminatedMay 31, 2023NORepinephrine added to dextrose 5%Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0743-2023Class IITerminatedMay 31, 2023EPINEPHrine added to 0.9% sodium chlorideLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0742-2023